Physician profile
Lori Bray Croft
NPI 1336140631
$13,401.32
in general payments reported to CMS, 2019-2025
17 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $11K · 2021: $43.30 · 2022: $327 · 2023: $490 · 2024: $202 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $11,537.13 | 2019-2022 | |
| Novo Nordisk INC | $341.53 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $282.40 | 2023-2025 | Mitraclip |
| Novartis Pharmaceuticals Corporation | $215.77 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $193.30 | 2021-2023 | Xarelto |
| Amgen INC. | $179.88 | 2019-2024 | Repatha |
| Philips North America LLC | $173.57 | 2022-2025 | Mcot |
| Pfizer INC. | $116.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $84.02 | 2019-2023 | Eliquis, Camzyos |
| Heartflow, INC. | $75.74 | 2023-2025 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.44 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $40.88 | 2025 | Farxiga |
| Esperion Therapeutics, INC. | $29.37 | 2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $29.15 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $24.64 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.19 | 2024 | Mounjaro, Zepbound |
| Ge Healthcare | $14.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Croft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.